
Some items listed as REQUIRING PRE-AUTHORISATION:
- Forxiga (Dapagliflozin)
- Byetta (Exenatide)
- Janumet (Metformin/Sitagliptin)
- Onglyza (Saxagliptin)
- Januvia (Sitagliptin)
- Galvus (Vildagliptin) + including Metformin combinations
- Liptruzet (Atorvastatin/Ezetimibe)
- Ezetrol (Ezetimibe)
- Inegy(Ezetimibe/Simvastatin)
Details regarding the EXCLUDED ITEMS:
- Trulicity (Dulaglutide)
- Jardiance (Empagliflozin)
- Xultophy (Insulin Degludec and Liraglutide)
- Soliqua (Insulin Glargine and Lixisenatide)
- Victoza (Liraglutide)
- Synjardy (Metformin and Empagliflozin)
- Ozempic (Semaglutide)
Recent Posts
Social Media Policy Action: Protecting Youth from Cognitive Risks
A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse
The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
In the interconnected landscape of pharmaceutical regulation and innovation, the Track One patent strategy in pharmaceuticals serves as an important component that influences the timing of mar...